Gilead Sciences (GILD - Free Report) closed at $70.86 in the latest trading session, marking a -1.5% move from the prior day. This change lagged the S&P 500's 1.09% gain on the day. At the same time, the Dow added 1.13%, and the tech-heavy Nasdaq gained 1.51%.
Coming into today, shares of the HIV and hepatitis C drugmaker had gained 2.32% in the past month. In that same time, the Medical sector gained 4.8%, while the S&P 500 gained 1.92%.
Wall Street will be looking for positivity from GILD as it approaches its next earnings report date. This is expected to be February 5, 2019. On that day, GILD is projected to report earnings of $1.74 per share, which would represent a year-over-year decline of 2.25%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $5.52 billion, down 7.26% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $6.93 per share and revenue of $21.85 billion, which would represent changes of -21.61% and -16.31%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for GILD. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. GILD is currently sporting a Zacks Rank of #1 (Strong Buy).
Valuation is also important, so investors should note that GILD has a Forward P/E ratio of 10.37 right now. For comparison, its industry has an average Forward P/E of 24.65, which means GILD is trading at a discount to the group.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 73, which puts it in the top 28% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow GILD in the coming trading sessions, be sure to utilize Zacks.com.